Who Qualifies for PRP and Who Should Consider Exosomes
Who is a better candidate for PRP and who is a better candidate for exosomes?
The choice between these two isn't really a contest over which one is stronger. It comes down to three things you can check before you spend a dollar: how much living follicle you've still got to rescue, what your own blood can actually deliver, and what you can commit to in time, money and follow-up. Get those three straight and the answer usually picks itself.
The strongest candidate for either injectable looks the same, an early or moderate case with hair still present, any reversible cause already corrected, and a willingness to pair the injection course with an evidence-backed daily therapy instead of treating it as a standalone cure.
What patient characteristics predict a strong response to platelet-rich plasma for hair loss?
The single strongest predictor is unglamorous: how much hair is still there. A scalp showing plenty of fine, short, pale miniaturized hairs under magnification has follicles that are shrunken but alive, and those are the units PRP can plausibly push back toward terminal growth. A smooth area with no visible openings has nothing to stimulate, and no injection protocol changes that.
- Miniaturized hair present: Shrunken but living follicles under magnification are the only units PRP can act on.
- Platelet concentration: Protocols aim for three to six times whole-blood baseline, roughly one million platelets per microlitre.
- Baseline workup: A complete blood count, ferritin, vitamin D and thyroid panel comes before the first session.
- Adherence: Three monthly sessions then maintenance every three to six months outperforms a single session.
Measured density gains from PRP are most commonly reported from three to six months, and standardized photographs taken before the first session are the only reliable way to judge them.
How does the degree of follicle miniaturization change which treatment makes sense?
Most people picture pattern loss as follicles dying off one by one. What actually happens is slower and more forgiving: each cycle runs a shorter growth phase and pushes out a thinner, paler shaft, while the bulb, the dermal papilla and the stem cell reservoir in the bulge stay put long after the visible hair stops counting for coverage. That surviving machinery is the only thing either injectable has to work with, so how much of it you've got left decides the whole call.
Neither PRP nor an exosome preparation creates a new follicle, so earlier miniaturization means better odds with either and late miniaturization means the money is usually better spent on transplantation or concealment.
Whose own blood makes platelet-rich plasma the weaker choice?
PRP is made from you, so every limitation in your blood becomes a limitation of the treatment. That isn't a technicality you can spin past, because if the sample can't reach the therapeutic concentration the evidence rests on, the session is going through the motions.
- Thrombocytopenia: Below the normal 150,000 to 400,000 per microlitre, a sample rarely spins to therapeutic strength.
- Platelet function disorders: The count looks normal while the platelets release poorly, as in uremia or liver disease.
- Antiplatelet medication: Long-term aspirin or clopidogrel blocks the activation step, and only your prescriber can pause it.
- Active hematologic disease: Malignancy, myelodysplastic syndrome, chemotherapy, sepsis or scalp folliculitis takes PRP off the table.
PRP is only ever as good as the sample it starts from, so a baseline platelet count comfortably inside the normal 150,000 to 400,000 per microlitre range is a practical prerequisite rather than a formality.
How does the stage and pattern of hair loss steer the decision between the two?
Staging does most of the triage before either product gets named. In men, Norwood 2 through 4 is the zone where injectables are usually offered, because there's still a mixed population of terminal and miniaturized hair to act on. In women, Ludwig I and II respond more predictably than Ludwig III, and the preserved frontal hairline gives you a broader target than a receding temple does.
| Criteria | Men | Women |
|---|---|---|
| Stage where injectables are offered | Norwood 2 to 4 | Ludwig I to II |
| Stage where grafting takes over | Norwood 5 and beyond | Ludwig III |
| Treatment field | Temples and vertex, narrow | Central part, broad |
| Least responsive area | Frontotemporal recession | Frontotemporal thinning, when present |
Telogen effluvium is the classic trap, since the shedding phase usually lasts less than six months and resolves on its own, so injecting into it buys a recovery that was coming anyway.
Which medical conditions and medications rule out one option but not the other?
Some exclusions hit both treatments and some separate them cleanly, and knowing which is which saves you a wasted consult. Anything that makes a needle into the scalp unwise stops both: an active local infection, an uncontrolled bleeding tendency, or poorly controlled diabetes with impaired healing. Pregnancy and breastfeeding usually mean postponing either, less because of a documented harm than because neither has been studied in that group.
Low ferritin, vitamin D deficiency, untreated hypothyroidism, rapid weight loss and recent isotretinoin or chemotherapy all cause shedding that resolves when the cause is addressed, which is what separates a real candidate from someone about to pay for a result they'd have had anyway.
How do cost and treatment frequency affect which option a person should commit to?
Price is where a lot of these decisions actually get made. In the United States clinics commonly quote several hundred to roughly a thousand dollars for a single PRP session, while exosome-based treatments are usually priced higher and often sold in packages or layered onto microneedling. Insurers treat both as cosmetic for pattern hair loss, so every dollar of it is yours.
| Criteria | PRP | Exosome-based |
|---|---|---|
| Per session in the US | Several hundred to about 1,000 dollars | High hundreds to low thousands |
| Standard course | Three monthly sessions, then maintenance | Often packaged or added to another session |
| Realistic first year | Roughly 2,000 to 5,000 dollars | Above the PRP equivalent |
| Insurance coverage | None for pattern hair loss | None for pattern hair loss |
Both treatments are maintenance rather than cures, and gains fade over roughly six to twelve months without repeat sessions, so anyone who can afford the induction course but not the maintenance is buying a temporary result.
What does the regulatory status of exosome products mean for who can actually receive them?
Regulation isn't a technicality here; it changes who should reasonably accept the treatment. In the United States the Food and Drug Administration hasn't approved any exosome product for hair loss or for any other cosmetic indication, and the agency has issued public safety notifications warning consumers about unapproved regenerative medicine products, including reports of serious adverse events.
- No reviewed specification: Nothing sets an agency-checked standard for potency, particle count or purity behind the word.
- Investigational standing: Donor-derived preparations fall outside minimal manipulation and homologous use, so they're investigational rather than routine.
- Marketing tell: An unapproved product can't lawfully be advertised as proven, so confident efficacy claims are a warning sign.
- Weaker recourse: If an adverse event happens, your options are thinner than with an approved therapy used on label.
The appropriate candidate for an exosome preparation is someone who understands they're accepting an investigational treatment, has been told so explicitly, and is comfortable with that, while anyone who wants an approved pathway and documented long-term safety data belongs on topical minoxidil or oral finasteride.
How do age and sex shape which of the two is the better fit?
Age is mostly standing in for two other measurements: how much follicle you've got left, and how well your own blood performs. Sex shapes the target rather than the mechanism, since female pattern loss thins the central part while preserving the hairline, and male loss concentrates at the temples and vertex. Between them, those two facts tilt most of these decisions before anyone opens a price list.
The frontotemporal recession men care about most is the least responsive region for either treatment, while the diffuse central thinning of female pattern loss gives injections a broader and more responsive field.
What should someone do when they are a poor candidate for both?
Being told no to both isn't the end of the road, and a clinic that never says it is the one to be wary of. A real no usually means something treatable is sitting in the way, and finding it is worth more to you than another product.
- Work it up properly: A scalp exam with magnification, complete blood count, ferritin, thyroid function, vitamin D, androgen status in women, and a biopsy where a scarring process is suspected.
- Correct what's reversible: Iron deficiency, thyroid disease, a medication side effect or a recent physiological shock all resolve without any injection.
- Build the daily foundation: Topical minoxidil and oral finasteride are the FDA approved options for pattern hair loss, finasteride for men only, with dutasteride and spironolactone prescribed off label under a physician's supervision.
- Add the low-risk adjuncts: Low-level laser devices hold FDA clearance for pattern hair loss, and microneedling has supporting evidence on its own rather than only as a delivery vehicle.
- Talk coverage, not growth: Where the openings are gone, a transplant consultation, scalp micropigmentation, a well-made hair system or a shorter cut are the honest options.
A no today is often a no for now, so anyone in an active shed, an untreated deficiency or an unresolved medical issue should be reassessed in six to twelve months, when the picture is stable and the same question finally has a real answer.
